(Total Views: 415)
Posted On: 08/16/2018 1:27:34 PM
Post# of 30015
![](/m/assets/46931549/no_avatar_available_thumb.jpg)
Quote:
Amarantus recently received an independent third-party valuation report which valued the Parkinson's disease levodopa-induced dyskinesia (PD-LID) indication for Eltoprazine in the US and Europe at $316 million. Amarantus management has outlined two distinct paths for Elto Pharma to extract as much value for the Eltoprazine asset for Amarantus as possible: 1) standalone private funding followed by a US or Hong Kong-based IPO, or 2) a business combination with an established clinical-stage biopharmaceutical company with strong management and an exceptional pipeline in which Amarantus could become a significant shareholder. Amarantus expects to make a final determination on the capital formation plan for Elto Pharma in the summer of 2018.
Definition of "Summer": The warmest season of the year, in the northern hemisphere from June to August.
I'm putting them on the clock ...
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)